<i>PNPLA3</i>rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism

Pan, Qin; Chen, Meimei; Zhang, Rui-Nan; Wang, Yuqin; Zheng, Rongqin; Mi, Yuqiang; Liu, Wenbin; Shen, Feng; Su, Qing; Fan, Jian‐Gao

doi:10.1155/2017/4740124

Cited by 4 publications

(4 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SNPs of patatin-like phospholipase domain-containing protein 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) are two common genetic determinants of NAFLD[ 76 , 77 ]. In cohort studies of biopsy-proven CHB patients, several SNPs of PNPLA3 were independently associated with steatosis, lobular inflammation, and steatohepatitis andwere similar to the findings of NAFLD studies[ 48 , 78 , 79 ], in which patients with SNPs of the T allele of rs1010023 in PNPLA3 were more susceptible to hepatic steatosis[ 78 ]. The T allele of rs58542926 in TM6SF2 has been associated with altered lipids and hepatic steatosis in CHB patients; this substitution was associated with increased HBV DNA[ 80 ].…”

Section: Mechanisms Of Interaction Between Hepatitis B and Steatosissupporting

confidence: 62%

Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion

Shi¹,

Yang²,

Fan³

2021

WJG

Self Cite

View full text Add to dashboard Cite

With the increasing incidence of obesity and metabolic syndrome worldwide, concomitant nonalcoholic fatty liver disease (NAFLD) in patients with chronic hepatitis B (CHB) has become highly prevalent. The risk of dual etiologies, outcome, and mechanism of CHB with concomitant NAFLD have not been fully characterized. In this review, we assessed the overlapping prevalence of metabolic disorders and CHB, assessed the risk of advanced fibrosis/hepatocellular carcinoma in CHB patients concomitant with NAFLD, and discussed the remaining clinical issues to be addressed in the outcome of such patients. We also explored the possible roles of hepatitis B virus in the development of steatosis and discussed difficultiesof histological evaluation. For CHB patients, it is important to address concomitant NAFLD through lifestyle management and disease screening to achieve better prognoses. The assessment of progressive changes and novel therapies for CHB patients concomitant with NAFLD deserve further research.

show abstract

Section: Mechanisms Of Interaction Between Hepatitis B and Steatosissupporting

confidence: 62%

Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion

Shi¹,

Yang²,

Fan³

2021

WJG

Self Cite

View full text Add to dashboard Cite

show abstract

“…In cohort studies of biopsy-proven CHB patients with or without HS, several SNPs of PNPLA3 were independently associated with steatosis and inflammation. In addition, when compared to the TT genotype, the C allele at PNPLA3 rs1010023 conferred a higher risk of HS in CHB patients (OR = 1.768, 95% CI: 1.027−3.105; P = 0.045) [65] . The T allele of rs58542926 in TM6SF2 has been associated with altered lipids and HS in CHB patients [66] .…”

Section: Interaction Of Chb and Nafldmentioning

confidence: 98%

“…In addition, when compared to the TT genotype, the C allele at PNPLA3 rs1010023 conferred a higher risk of HS in CHB patients (OR = 1.768, 95% CI: 1.027−3.105; P = 0.045). [ 65 ] The T allele of rs58542926 in TM6SF2 has been associated with altered lipids and HS in CHB patients. [ 66 ] The genetic and metabolic changes related to HBV infection at the cellular level could help explain the clinical outcomes, but phenotypic differences related to NAFLD at the individual level require further study.…”

Section: Interaction Of Chb and Nafldmentioning

confidence: 99%

Clinical impact and mechanisms in hepatitis B virus infection concurrent with non-alcoholic fatty liver disease

Tong

Song

Yin

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) virus infection is an important threat to global health despite the administration of vaccines and the use of antiviral treatments. In recent years, as the prevalence of obesity and metabolic syndrome has increased, non-alcoholic fatty liver disease (NAFLD) in patients with CHB has become more common. Both diseases can lead to liver fibrosis and even hepatocellular carcinoma, but the risk of dual etiology, outcome, and CHB combined with NAFLD is not fully elucidated. In this review, we assess the overlapping prevalence of NAFLD and CHB, summarize recent studies of clinical and basic research related to potential interactions, and evaluate the progressive changes of treatments for CHB patients with NAFLD. This review increases the understanding of the relationship and mechanisms of interaction between steatosis and hepatitis B virus infection, and it provides new strategies for the future clinical management and treatment of CHB combined with NAFLD.

show abstract

“…In addition, different alleles of PNPLA3 rs738409 were associated with various responses to lifestyle interventions or pharmacotherapies for NAFLD 52 . In the context of HBV infection, the C allele at PNPLA3 rs1010023 might predispose patients with CHB to hepatic steatosis 53 …”

Section: The Characteristics Of Nafld/nash In Chinamentioning

confidence: 99%

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Liu

Hong

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim With industrialization and spread of the westernized lifestyle, the number of people affected by non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) is growing rapidly in China; this has become a major public health concern. To better understand the burden and characteristics of NAFLD/NASH in China, we aim to perform a narrative review of the literature published in this field. Materials and Methods We carried out a comprehensive electronic search of five English‐language and three Chinese‐language databases, to identify studies regarding NAFLD or NASH published from inception to November 30, 2022. Epidemiological studies of NAFLD/NASH in China were particularly noticed and summarized. We also searched the http://www.clinicaltrials.gov and http://www.chictr.org.cn websites for the registered trials on the treatment of the disease led by Chinese investigators or located in China. Results The increasing rate of NAFLD prevalence in China is strikingly high, reaching more than twice that in western countries. The prevalence of NAFLD is nearly 30% of the general Chinese population, making it the leading cause of chronic liver diseases. The prevalence of NAFLD/NASH varies between provinces/regions, age groups, sexes, and individuals with different metabolic profiles. NAFLD co‐exists in many Chinese patients with chronic hepatitis B. Since 2020, more Chinese studies have used the term metabolic‐associated fatty liver disease (MAFLD), emphasizing the underlying metabolic disorders that occur concurrently with this disease. Several clinical trials involving lifestyle interventions, antidiabetic drugs, or traditional Chinese medicines, registered by Chinese investigators, have been completed or are ongoing. Moreover, several innovative targeted therapies developed in China are revolutionizing the treatment of NAFLD/NASH. Conclusions NAFLD has cast a heavy burden on the Chinese healthcare system. Chinese scholars are making efforts to achieve the optimal management of this disease.

show abstract

PNPLA3rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism

Cited by 4 publications

References 57 publications

Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion

Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion

Clinical impact and mechanisms in hepatitis B virus infection concurrent with non-alcoholic fatty liver disease

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Contact Info

Product

Resources

About